Alzheimer's Disease Brain: Alterations in RNA Levels and in a Ribonuclease-Inhibitor Complex
The DOI matches its Crossref record.
Abstract
A macromolecular alteration occurs at the posttranscriptional level in the Alzheimer's disease (AD) brain. Compared with age-matched controls, total cellular RNA and polyadenylated RNA were substantially reduced in the AD cortex with many neuritic plaques and neurofibrillary tangles. RNA changes are associated with a significant increase in alkaline ribonuclease activity due to an abnormality in the ribonuclease-inhibitor complex. The decrease in protein synthesis in the AD brain, previously observed in patients severely affected with AD, and in translation systems in vitro with AD cortical messenger RNA, may be partly related to an enzyme-inhibitor alteration that affects RNA levels and activity. Decreased protein synthesis therefore may contribute to the characteristic decline in certain neurotransmitter enzymes and to the loss of neurons in the AD brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Whittemore, S. R., & Seiger, Å. (1987) · Brain Research Reviews · doi:10.1016/0165-0173(87)90008-7 · Cited by 492
Sultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478
“In particular, markers of lipid peroxidation have been found to be elevated in brain tissues and body fluids in several neurodegenerative diseases, including Alzheimer disease (AD), Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), Huntington disease (HD), and Down syndrome (DS) [17–21].”
Ribosome Dysfunction Is an Early Event in Alzheimer's Disease
Ding, Q., Markesbery, W. R., Chen, Q., Li, F., & Keller, J. N. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3040-05.2005 · Cited by 433
Interaction of aldehydes derived from lipid peroxidation and membrane proteins
Pizzimenti, S., Ciamporcero, E., Daga, M., Pettazzoni, P., Arcaro, A., Cetrangolo, G., Minelli, R., Dianzani, C., Lepore, A., Gentile, F., et al. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00242 · Cited by 380
Lipid peroxidation and neurodegenerative disease
Reed, T. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.027 · Cited by 379
Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron
Honda, K., Smith, M. A., Zhu, X., Baus, D., Merrick, W. C., Tartakoff, A. M., Hattier, T., Harris, P. L., Siedlak, S. L., Fujioka, H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500526200 · Cited by 280
Pre‐and Postmortem Influences on Brain RNA
Barton, A. J. L., Pearson, R. C. A., Najlerahim, A., & Harrison, P. J. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03532.x · Cited by 268
Reed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., Coccia, R., Markesbery, W. R., & Butterfield, D. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.007 · Cited by 257
“Numerous studies have provided indirect evidence that suggests alterations in protein synthesis may occur in AD (Chang et al., 2002; Ding et al., 2005; Ferrer, 2002; Li et al., 2004; Sajdel-Sulkowska and Marotta, 1984) and decreased protein synthesis in AD and MCI (Ding et al., 2006, 2005).”
Decrease in Peptide Methionine Sulfoxide Reductase in Alzheimer's Disease Brain
Gabbita, S. P., Aksenov, M. Y., Lovell, M. A., & Markesbery, W. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731660.x · Cited by 256
Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome
Hernández‐Ortega, K., Garcia‐Esparcia, P., Gil, L., Lucas, J. J., & Ferrer, I. (2016) · Brain Pathology · doi:10.1111/bpa.12335 · Cited by 245
“ribosomes and abnormal expression levels of certain transcription factors, and impaired protein synthesis in cortical areas in cases with mild cognitive impairment and dementia caused by AD (26, 34, 62, 64, 84).”
BackgroundPerluigi, M., Coccia, R., & Butterfield, D. A. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4406 · Cited by 229
“Numerous studies have provided indirect evidence that suggests alterations in protein synthesis may occur in AD (58, 74, 176).”
Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients
Mullaart, E., Boerrigter, M. E. T. I., Ravid, R., Swaab, D. F., & Vijg, J. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90542-8 · Cited by 201
mTOR‐dependent signalling in Alzheimer's disease
Pei, J., & Hugon, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00509.x · Cited by 190
Nuclear Tau and Its Potential Role in Alzheimer’s Disease
Bukar Maina, M., Al-Hilaly, Y., & Serpell, L. (2016) · Biomolecules · doi:10.3390/biom6010009 · Cited by 161
Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology
Grothe, M. J., Sepulcre, J., Gonzalez-Escamilla, G., Jelistratova, I., Schöll, M., Hansson, O., Teipel, S. J., & Initiative, A. D. N. (2018) · Brain · doi:10.1093/brain/awy189 · Cited by 142
Tau drives translational selectivity by interacting with ribosomal proteins
Koren, S. A., Hamm, M. J., Meier, S. E., Weiss, B. E., Nation, G. K., Chishti, E. A., Arango, J. P., Chen, J., Zhu, H., Blalock, E. M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01970-9 · Cited by 122
“In fact, hyperphosphorylated tau complexes with ribosomes in early stages of pathological tau aggregation [25, 38, 39, 42–44, 57], and tauopathic brains have reduced ribosomal function [14, 28, 32, 50].”
BackgroundRoses, A. D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s340 · Cited by 86
“Subsequently, over more than a decade, the biological expression of apoE in human neurons was confirmed as distinct from rodent brain [7,8] Proteomic experiments and positron emission tomography data have led to a series of clinical trials with agents selected to increase glucose utilization.”
Di Domenico, F., Head, E., Butterfield, D. A., & Perluigi, M. (2014) · Advances in Geriatrics · doi:10.1155/2014/527518 · Cited by 50
“[100, 101].”
InfluentialKoren, S. A., Galvis-Escobar, S., & Abisambra, J. F. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104939 · Cited by 49
Metadata
- Authors
- Sajdel-Sulkowska, E. M., & Marotta, C. A.
- Venue
- Science
- Published
- 1984-08-31
- Volume
- 225
- Issue
- 4665
- Pages
- 947-949
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2079193268
- Cited by
- 181
- References
- 0
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.